Sistema para creación y gestión de colecciones on-line con fines educativos

El juego es un instrumento de aprendizaje extremadamente valioso, no obstante, está muy poco explotado en la enseñanza universitaria. Es por ello que la finalidad de este Trabajo de Fin de Grado fue el desarrollo de una aplicación web para la realización de coleccionables temáticos. Se pretende construir una herramienta que permita incentivar el aprendizaje de los alumnos y lo convierta en una experiencia más amena de la mano de las nuevas tecnologías, pudiendo consolidar lo aprendido y brindando a los estudiantes una herramienta para el refuerzo de los conocimientos impartidos en las aulas. De la misma forma se buscó facilitar al profesorado, la incorporación de la evaluación al proceso de la enseñanza, permitiendo un control más exhaustivo de las asignaturas y del punto en el que se encuentra cada alumno en relación con los conceptos recibidos en las clases. Se obtiene así una nueva metodología para enseñar y aprender de una manera fuera de los modelos tradicionales utilizados hasta ahora

Tic-tac, colecciona UCM. Tecnología de la información y las comunicaciones aplicada a las técnicas de aprendizaje cooperativo

Depto. de Física de MaterialesSección Deptal. de Arquitectura de Computadores y Automática (Físicas)Fac. de Geografía e HistoriaFac. de Ciencias FísicasFALSEsubmitte

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

Background: Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study. Methods: From the GLORIA-AF Registry Phase II-III (November 2011-December 2014 for Phase II, and January 2014-December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with ClinicalTrials.gov, NCT01468701, NCT01671007, and NCT01937377. Findings: 34,421 patients were included (70.0 ± 10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n = 6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n = 15,449, 56.1%) and North America (n = 8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals (CI): 0.23 [0.22-0.25] and 0.66 [0.61-0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67-1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76-0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding. Interpretation: Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis. Funding: The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH